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NUCLEOTIDE (DNA) SEQUENCE FOR crnws VALENCENE SYNTHASE 
GENE (CVS) 
SEQ ID NO.: 1 
LENGTH: 1710 NT 
64 ATGTCGTCTGGAGAAACATTTCGTCCTACTGCAGATTTCCATCCT 
109 AGTTTATGGAGAAACCATTTCCTCAAAGGTGCTTCTGATTTCAAG 
154 ACAGTTGATCATACTGCAACTCAAGAACGACACGAGGCACTGAAA 
199 GAAGAGGTAAGGAGAATGATAACAGATGCTGAAGATAAGCCTG TT 
244 CAGAAGTTACGCTTGATTGATGAAGTACAACGCCTGGGGGTGGCT 
289 TATCACTTTGAGAAAGAAATAGAAGATGCAATACTAAAATTATGT 
334 CCAATCTATATTGACACTAATAGAGCTGATCTCCACACCGTTTCC 
379 CTTCATTTTCGATTGATTAGGCAGCAAGGAATCAAGATTTCATGT 
424 GATGTGTTTGAGAAGTTCAAAGATGATGAGGGTAGATTCAAGTCA 
469 TCGTTGATAAACGATGTTCAAGGGATGTTAAGTTTGTACGAGGCA 
514 GCATACATGGCAGTTCGCGGAGAACATATATTAGATGAAGCCATT 
559 GCTTTCACTACCACTCACCTGAAGTCATTGGTAGCTCAGGATCAT 
604 GTAACCCCTAAGCTTGCGGAACAGATAAATCATGCTTTATACCGT 
649 CCTCTTCGTAAAACCCTACCAAGATTAGAGGCGAGGTATTTTATG 
694 TCCATGATCAATTCAACAAGTGATCATTTATACAATAAAACTCTG 
739 CTGAATTTTGCAAAGTTAGATTTTAACATATTGCTAGAGCCGCAC 
784 AAGGAGGAACTCAATGAATTAACAAAGTGGTGGAAAGATTTAGAC 
829 TTCACTACAAAACTACCTTATGCAAGAGACAGATTAGTGGAGTTA 
974 TAZTTTTGGGATTTAGGGACATACTTCGAGCCTCAATATGCATTT 
919 GGGAGAAAGATAATGACCCAATTAAATTACATATTATCCATCATA 
964 GATGATACTTATGATGCGTATGGTACACTTGAAGAACTCAGCCTC 
1009 TTTACTGAAGCAGTTCAAAGATGGAATATTGAGGCCGTAGATATG 
1054 CTTCCAGAATACATGAAATTGATTTACAGGACACTCTTAGATGCT 
1099 TTTAATGAAATTGAGGAAGATATGGCCAAGCAAGGAAGATCACAC 
1144 TGCGTACGTTATGCAAAAGAGGAGAATCAAAAAGTAATTGGAGCA 
1189 TACTCTGTTCAAGCCAAATGGTTCAGTGAAGGTTACGTTCCAACA 
1234 ATTGAGGAGTATATGCCTATTGCACTAACAAGTTGTGCTTACACA 
1279 TTCGTCATAACAAATTC'CTTCCTTGGCATGGG'IGATTTTGCAACT 
1324 AAAGAGGTTTTTGAATGGATCTCCAATAACCCTAAGGTGTTAAAA 
1369 GCAGCATCAGTTATCTGCAGACTCATGGATGACATGCAAGGTCAT 
1414 GAGTTTGAGCAGAAGAGAGGACATGTTGCGTCAGCTATTGAATCT 
1459 TACACGAAGCAGCATGGTGTOTCTAAGGAAGAGGCAATTAAAATG 
1504 TTTGAAGAAGAAGTTGCAAATGCATGGAAAGATATTAACGAGGAG 
1549 TTGATGATGAAGCCAACCGTCGTTGCCCGACCACTGCTCGGGACG 
1594 ATTCTTAATCTTGCTCGTGCAATTGATTTTATTTACAAAGAGGAC 
1639 GACGGCTATACGCATTCTTACCTAATTAAAGATCAAATTGCTTCT 
G TGC TAGGAGACCACGT TCCAT T T TGA 1710 
FIG. 5 
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SESQUITERPENE SYNTHASE GENE AND 
PROTEIN 
RELATED APPLICATIONS 
This application is a continuation of allowed US. patent 
application Ser. No. 12/259,497, ?led Oct. 28, 2008, which 
claims bene?t of priority under 35 U.S.C. 120 to US. patent 
application Ser. No. 10/899,356, ?led on Jul. 26, 2004, now 
US. Pat. No. 7,442,785, issued Oct. 28, 2008, which claims 
bene?t of priority under 35 U.S.C. 119(e) to US. Provisional 
Application No. 60/489,514, ?led Jul. 24, 2003. The disclo 
sures of the above referenced applications are incorporated by 
reference in their entirety herein. 
FIELD OF THE INVENTION 
This invention relates generally to the ?eld of production of 
valencene and nootkatone, and more particularly relates to 
the discovery of a valencene synthase gene and related pro 
tein, which provides a pathway for generating highly pure 
valencene which can be converted into the ?avorant, nootka 
tone. 
BACKGROUND 
Terpenes are a diverse family of compounds with carbon 
skeletons composed of ?ve-carbon isoprene units. Approxi 
mately 20,000 different terpenes and terpenoids (compounds 
of terpene origin whose carbon skeleton has been altered or 
rearranged) have been identi?ed to date, representing only a 
small fraction of the estimated natural variation. Terpenes are 
commonly isolated from the essential oils of plants. Essential 
oils often have pleasant tastes or aromas, and they are widely 
used as ?avorings, deodorants, and medicines. 
Sesquiterpenes are terpenes with 15 carbon atoms (three 
isoprene units). The plant kingdom contains the highest diver 
sity of sesquiterpenes. Often they play a role in defense of the 
plants against pathogens, insects and herbivores and for 
attraction of pollinating insects. 
Valencene (1 ,2,3,5,6,7,8,8a-octahydro-7-isopropenyl-1, 
8a-dimethyl-naphthalene) and nootkatone (4,4a,5,6,7,8 
hexahydro-6-isopropenyl-4,4-a-dimethyl-2(3H)-naphtal 
enone) are just two examples of sesquiterpenes that are 
derived from cyclization of the ubiquitous pyrophosphate 
intermediate farnesyl diphosphate. Nootkatone is formed by 
the oxidation of valencene. 
Valencene and nootkatone are compounds of natural ori 
gin, and are natural constituents of citrus oils, such as orange 
and grapefruit. Because of its excellent organoleptic qualities 
and in particular its typical grapefruit taste, nootkatone is a 
widely used ingredient in perfumery and the ?avor industry. 
Alternatively, nootkatone may be used as an insecticide. 
Valencene, the starting material for the generation of nootka 
tone (either biologically or chemically), is also used as a 
?avorant and fragrance. 
Several methods to purify sesquiterpenes, such as valen 
cene and nootkatone, from citrus fruits or to maintain high 
levels of these sesquiterpenes in citrus fruit extracts have been 
described in the prior art. These methods are described below. 
Japikse et al., in US. Pat. No. 4,693,905, claimed a method 
of extracting concentrated orange ?avor and aroma compo 
sitions from natural orange essence oil by using a dense 
solvent gas. Their procedure entailed (a) contacting natural 
orange essence oil with a solvent gas having a temperature 
between its critical temperature and 100° C., and having a 
reduced pressure between about 0.56 and about 1.31 (where 
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reduced pressure is de?ned as the extraction pressure of the 
solvent gas divided by its critical pressure), to extract ?avor 
and aroma compounds; (b) separating the solvent gas and 
dissolved compounds from the remaining undissolved com 
pounds; and (c) separating the dissolved compounds from the 
solvent gas. 
Rich, in US. Pat. No. 4,973,485, discloses a method of 
producing aqueous orange stripper essences and orange strip 
per oils with high ratios of valencene to the less desirable 
orange ?avor compounds. This procedure involves the fol 
lowing steps: (a) heating an orange fed juice stream to a 
temperature of 37.7° C. to 71 ° C.; (b) stripping the heated feed 
juice with steam at a steam: soluble solids ratio of 0.3 to 1.5, at 
a temperature of 37.7° C. to 71° C. and at a stripping column 
pressure of less than 9 inches of Hg, absolute; (c) condensing 
the stripped volatiles at a temperature of 406° C. to —196° C.; 
(d) centrifuging the condensate in a continuous stacked disk 
hermetic centrifuge to produce two clear phases; and (e) 
removing the aqueous orange stripper essence phase. 
In US. Pat. No. 5,260,086 Downton et al. describe a pro 
cess for making an aseptic citrus sensible pulp/ juice slurry by 
extracting and removing juice from citrus juice containing 
sensible pulp. After this process is complete, ?avorants, such 
as valencene are added to make up for those that are lost 
during this extraction process. 
Hiramoto et al., in US. Pat. No. 6,495,193 prepares a citrus 
?avor from a low-boiling part of a cold pressed oil by a 
hydrate alcohol solvent extraction. To maintain the stability 
of the ?avor, a stabiliZing coumarin analogue component is 
added. 
In a US patent application, publication number US 
20030185956, Gradley claims a separation method for 
extracting desired sesquiterpene aroma compounds, such as 
valencene and nootkatone, from an aqueous phase by sepa 
rating the aqueous mixture from a water-immiscible hydro 
phobic phase by means of a hydrophilic membrane and allow 
ing the desired components to move out off the aqueous phase 
through the membrane and into the hydrophobic phase. 
Kotachi et al., in US patent application, publication num 
ber 20030203090, teaches of a process for preparing orange 
oil useful as fragrance or ?avor material, by mixing raw 
material oil containing valencene with a high-boiling solvent 
having a boiling point exceeding 240° C. under normal pres 
sure, to give a mixture, and fractionally distilling the mixture 
obtained. 
Nootkatone is a high demand, high value ?avorant added to 
many of the commercial soft drinks sold worldwide. Cur 
rently, the practice of extracting nootkatone from citrus pulp 
and rind is considered an expensive and somewhat unreliable 
process. Nootkatone can be synthesized by the oxidation of 
valencene. The valencene starting material is expensive and is 
easily degraded during evaporative heat concentration pro 
cesses typically used to remove the bulk of water from the 
feed juice. Thus, current methods to purify valencene from 
citrus fruits are costly, di?icult, and are limited by what the 
fruit can deliver. Moreover, such methods are vulnerable to 
interruptions in the supply of citrus fruits, which is dependent 
on the weather. A frost or hailstorm in a major citrus fruit 
growing region such as Florida can interrupt the supply. Fur 
thermore, methods to produce nootkatone that consume 
valencene are quite costly, and thus not commercially desir 
able. Therefore, there is a need for an alternative means for 
preparing valencene and nootkatone. 
SUMMARY OF THE INVENTION 
In one embodiment, the invention relates to isolated 
nucleic acids that encode a sesquiterpene synthase. The 
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invention provides an isolated nucleic acid selected from: (a) 
a nucleic acid comprising the nucleotide sequence substan 
tially as set out in SEQ ID NO: 1; (b) a nucleic acid encoding 
the polypeptide substantially set out in SEQ ID NO: 4; and (c) 
a nucleic acid that hybridizes to the nucleic acid of (a) or (b) 
under low stringency conditions, wherein the polypeptide 
encoded by said nucleic acid is a sesquiterpene synthase. 
Other embodiments include: a polypeptide encoded by a 
nucleic acid of the invention; a host cell comprising a nucleic 
acid of the invention; a non-human organism modi?ed to 
harbor a nucleic acid of the invention; and methods of pro 
ducing a polypeptide comprising culturing host cells of the 
invention. 
In another embodiment, the invention provides an isolated 
polypeptide comprising an amino acid sequence substantially 
as set out in SEQ ID NO: 4. 
In a further embodiment, the invention provides a vector 
comprising at least one nucleic acid chosen from (a) a nucleic 
acid comprising the nucleotide sequence substantially as set 
out in SEQ ID NO: 1; (b) a nucleic acid encoding the polypep 
tide substantially set out in SEQ ID NO: 4; and (c) a nucleic 
acid that hybridizes to the nucleic acid of (a) or (b) under low 
stringency conditions, wherein the polypeptide encoded by 
said nucleic acid is a sesquiterpene synthase. Other embodi 
ments include, methods of making a recombinant host cell 
comprising introducing a vector of the invention into a host 
cell. 
In a further embodiment, the invention relates to isolated 
nucleic acids that encode a sesquiterpene synthase. The 
invention provides an isolated nucleic acid selected from: (a) 
a nucleic acid comprising the nucleotide sequence substan 
tially as set out in SEQ ID NO: 5 or SEQ ID NO: 6; (b) a 
nucleic acid encoding the polypeptide substantially set out in 
SEQ ID NO: 7 or SEQ ID NO: 8; and (c) a nucleic acid that 
hybridizes to the nucleic acid of (a) or (b) under low strin 
gency conditions, wherein the polypeptide encoded by said 
nucleic acid is a sesquiterpene synthase. Other embodiments 
include: a polypeptide encoded by a nucleic acid of the inven 
tion; a host cell comprising a nucleic acid of the invention; a 
non-human organism modi?ed to harbor a nucleic acid of the 
invention; and methods of producing a polypeptide compris 
ing culturing host cells of the invention. 
In another embodiment, the invention provides an isolated 
polypeptide comprising an amino acid sequence substantially 
as set out in SEQ ID NO: 7 or SEQ ID NO: 8. 
In a further embodiment, the invention provides a vector 
comprising nucleic acid chosen from (a) a nucleic acid com 
prising the nucleotide sequence substantially as set out in 
SEQ ID NO: 5 or SEQ ID NO: 6; (b) a nucleic acid encoding 
the polypeptide substantially set out in SEQ ID NO: 7 or SEQ 
ID NO: 8; and (c) a nucleic acid that hybridizes to the nucleic 
acid of (a) or (b) under low stringency conditions, wherein the 
polypeptide encoded by said nucleic acid is a sesquiterpene 
synthase. Other embodiments include, methods of making a 
recombinant host cell comprising introducing a vector of the 
invention into a host cell. 
In one embodiment, the invention provides a method of 
making at least one sesquiterpene synthase comprising cul 
turing a host cell modi?ed to contain at least one nucleic acid 
sequence under conditions conducive to the production of 
said at least one sesquiterpene synthase. In one embodiment, 
the at least one nucleic acid is chosen from (a) a nucleic acid 
comprising the nucleotide sequence substantially as set out in 
SEQ ID NO: 1, SEQ ID NO: 5 or SEQ ID NO: 6; (b) a nucleic 
acid encoding the polypeptide substantially set out in SEQ ID 
NO: 4, SEQ ID NO: 7 or SEQ ID NO: 8; and (c) a nucleic acid 
that hybridizes to the nucleic acid of (a) or (b) under low 
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stringency conditions, wherein the polypeptide encoded by 
said nucleic acid is a sesquiterpene synthase. The host may be 
chosen from, for example, plants, microorganisms, bacterial 
cells, yeast cells, plant cells, and animal cells. 
In another embodiment the invention provides a method of 
making at least one terpenoid comprising: 
1) contacting at least one acyclic pyrophosphate terpene pre 
cursor with at least one polypeptide encoded by a nucleic 
acid of the current invention. In one embodiment, the 
nucleic acid is chosen from (a) a nucleic acid comprising 
the nucleotide sequence substantially as set out in SEQ ID 
NO: 1, SEQ ID NO: 5 or SEQ ID NO: 6; (b) a nucleic acid 
encoding the polypeptide substantially set out in SEQ ID 
NO: 4, SEQ ID NO: 7 or SEQ ID NO: 8; and (c) a nucleic 
acid that hybridizes to the nucleic acid of (a) or (b) under 
low stringency conditions, wherein the polypeptide 
encoded by said nucleic acid is a sesquiterpene synthase, 
2) isolating at least one terpenoid produced in 1). 
In one embodiment, the at least one terpenoid is chosen 
from the group consisting of sesquiterpene. 
In a further embodiment, the at least one acyclic pyrophos 
phate terpene precursor is famesyl-diphosphate (FPP). The 
sesquiterpene produced by the methods of the invention 
include, but are not limited to, valencene, valencene deriva 
tives, valencene fragments, and compounds having the citrus 
valencene carbon skeleton. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 shows the conversion of FPP to the sesquiterpene 
reaction products 5-epi-aristolochene, premnaspirodiene and 
valencene catalyzed by Nicotiana tabacum epi-aristolochene 
synthase (TEAS), Hyoscyamus mulicus premnaspirodiene 
synthase (HPS), and Citrus paradisi valencene synthase 
(CVS), respectively. 
FIG. 2 illustrates a mechanism for the enzyme catalyzed 
development of regio- and enantio-speci?city in eremo 
philanes. Upon loss of the diphosphate from C1 and genera 
tion of the initial carbocation, a chiral center arises from the 
?rst attack on either the si or re face of sp2 hybridized C10 
yielding either (10R)-germacrene A or (10S)-germacrene A. 
Two additional chiral centers develop upon formation of an 
internal bond between C2 and C7. This process of proton 
initiated, internal cyclization (illustrated as transition states) 
requires that the p-orbitals of sp2 hybridized C2 and C7 face 
and align with each other. The 4 possible combinations of 
overlapping orbitals are dependent on the orientation of the 
respective p orbitals either above or below the plane of the 
eudesmalyl carbocation intermediate. The possible re and si 
orientations of the C2 p-orbitals are given on the vertical axis 
of the diagram and those for C7 depicted on the horizontal 
axis. These orientations direct the stereochemistry of the 
ensuing methyl migrations and hydride shifts (not illustrated) 
and de?ne, as a consequence, the ?nal chirality of the methyl 
substitutions at C2 and C3. Subsequent to these rearrange 
ments, a tertiary carbocation centered at C7 is formed (an 
eremophilyl cation, not shown) and alternate elimination of a 
proton from C6 or C8 give two subclasses of double bond 
regioisomers, illustrated as layers. Known eremopliilanes are 
noted by their common name. 
FIG. 3 illustrates a proposed pathway for the biosynthesis 
of nootkatone in citrus. The scheme suggests at least two 
steps, the ?rst step is catalyzed by the sesquiterpene synthase 
of the current invention, denoted as “1” in the ?gure, which 
leads to the production of valencene and the second step 
consisting of a regio-speci?c hydroxylation, followed by oxi 
dation. The second step could be catalyzed by a single mul 
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tifunctional hydroxylase or could involve sequential enzyme 
mediated reactions, and which are denoted as “2” in the 
?gure. 
FIG. 4 illustrates a sequence alignment of amino acids 
lining the active site (1st tier) and those within 3 A of the 
active site residues (2nd tier) of TEAS with the corresponding 
positions of CVS. For uniformity, the TEAS amino acids 
numbering was used, and thus the corresponding CVS amino 
acids renumbereditermed comparative numbering. The 1st 
tier residues lie within 3 A of a substrate analog co-crystal 
lized within the TEAS enzyme and includes residues making 
up the J/ K loop which clamps down over the active site upon 
substrate binding. The corresponding residues within CVS 
(valencene synthase) were initially identi?ed by primary 
sequence alignment, then visual inspection of the relevant 
CVS sequences overlaid on the TEAS 3-dimensional struc 
ture. Residues different from TEAS are highlighted. 
FIG. 5 shows SEQ ID NO: 1, which is the DNA sequence 
for the citrus valencene synthase gene from Citrus paradis 
isolated in the current invention. 
FIG. 6 shows SEQ ID NO: 4, which is the protein sequence 
for the citrus valencene synthase from Citrus paradisi. 
FIG. 7 illustrates reaction product analysis of citrus valen 
cene synthase (CVS) incubated at pH 7.5. Lysate of E. coli 
expressing the CVS cDNA was incubated with FPP at pH 7.5 
and total pentane extractable products evaluated by GC-MS 
(upper panel). The mass spectrum of the reaction product 
corresponding to peakA (middle panel) is compared to that of 
authentic valencene in the lower panel. The mass spectrum of 
peak B is identical to that for beta-elemene, the thermal 
induced rearrangement product of germacrene A. 
FIG. 8 illustrates a mass spectrum for the peak with a 
retention time of 7.38 minutes from FIG. 7 (top) compared to 
the spectra for beta-elemene published by the NIST library 
(bottom). 
FIG. 9 illustrates mass spectrum for the peak with a reten 
tion time of 8.89 in FIG. 7 (top) compared to that for valen 
cene purchased from Fluka Chemical Company (bottom). 
FIG. 10 illustrates that the reaction product speci?city of 
citrus valencene synthase (CVS) is pH dependent. Partially 
puri?ed synthase isolated from E. coli expressing the CVS 
cDNA was incubated with FPP at the indicated pH values and 
ethylacetate extracts were examined directly by GC-MS. 
Absolute values for valencene (solid symbols) and germa 
crene A (measured as the thermally rearranged product [3-el 
emene) (open symbols) are reported and represent greater 
than 95% of the total reaction products at all pHs. 
FIG. 11 is a sequence alignment of amino acids lining the 
active site (1 st tier) of TEAS with the corresponding positions 
of HPS and CVS. The 1st tier residues lie within 3 A of a 
substrate analog co-crystallized within the TEAS enzyme and 
includes residues making up the J/ K loop which clamps down 
over the active site upon substrate binding. The correspond 
ing residues within the other terpene synthases were initially 
identi?ed by primary sequence alignment, then visual inspec 
tion of the relevant sequences overlaid on the TEAS 3 -dimen 
sional structure. Residues in CVS differing from TEAS are 
highlighted. 
FIG. 12 shows SEQ ID NO: 5, which is the DNA sequence 
from SEQ ID NO: 1 corresponding to the amino acids form 
ing Tier 1. Comparative numbering from Tier 1 amino acid 
residues is also shown (SEQ ID NO: 7). 
FIG. 13 shows SEQ ID NO: 6, which is the DNA sequence 
from SEQ ID NO: 1 corresponding to the amino acids form 
ing Tier 2. Comparative numbering from Tier 2 amino acid 
residues is also shown (SEQ ID NO: 8). 
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FIG. 1411 shows the absolute amino acid sequence from 
SEQ ID NO: 4 corresponding to the Tier 1 amino acid resi 
dues. FIG. 14b shows the comparative amino acid sequence 
of the Tier 1 amino acid residues (SEQ ID NO: 7). 
FIG. 1511 shows the absolute amino acid sequence from 
SEQ ID NO: 4 corresponding to Tier 2 amino acid residues. 
FIG. 15b shows the comparative amino acid sequence of the 
Tier 2 amino acid residues (SEQ ID NO: 8). 
FIG. 16 is a sequence alignment of the amino acid 
sequence of TEAS active site compared to the amino acid 
sequence of the CVS active site. The alignment maximizes 
residue similarities and introduce gaps where necessary. 
Absolute amino acid numbering is shown for CVS, thus 
amino acid numbering from SEQ ID NO: 4 is shown for CVS. 
FIG. 17 is a chart showing the TEAS Tier 1 and Tier 2 
amino acid residues in column 1; the CVS Tier 1 and Tier 2 
amino acid residues with absolute numbering in column 2; 
and the CVS Tier 1 and Tier 2 amino acid residues with 
comparative numbering in column 3. 
DETAILED DESCRIPTION OF THE INVENTION 
Abbreviations and Terms 
In accordance with the present invention and as used 
herein, the following terms and abbreviations are de?ned with 
the following meanings, unless explicitly stated otherwise. 
These explanations are intended to be exemplary only. They 
are not intended to limit the terms as they are described or 
referred to throughout the speci?cation. Rather, these expla 
nations are meant to include any additional aspects and/or 
examples of the terms as described and claimed herein. 
The following abbreviations are used herein: 
As used herein, a “derivative” is any compound obtained 
from a known or hypothetical compound and containing 
essential elements of the parent substance. 
The phrase “substantially identical” means that a relevant 
sequence is at least 70%, 75%, 80%, 85%, 90%, 92%, 95% 
96%, 97%, 98%, or 99% identical to a given sequence. By 
way of example, such sequences may be allelic variants, 
sequences derived from various species, or they may be 
derived from the given sequence by truncation, deletion, 
amino acid substitution or addition. Percent identity between 
two sequences is determined by standard alignment algo 
rithms such as ClustalX when the two sequences are in best 
alignment according to the alignment algorithm. 
As used herein, the term “hybridization” or “hybridizes” 
under certain conditions is intended to describe conditions for 
hybridization and washes under which nucleotide sequences 
that are signi?cantly identical or homologous to each other 
remain bound to each other. Appropriate hybridization con 
ditions can be selected by those skilled in the art with minimal 
experimentation as exempli?ed in Ausubel, F. A., et al., eds., 
Current Protocols in Molecular Biology Vol. 2, John Wiley 
and Sons, Inc., New York (1995). Additionally, stringency 
conditions are described in Sambrook et al. Molecular Clon 
ing: A Laboratory Manual, 2nd ed., Cold Spring Harbor 
Laboratory Press, New York (1989). Variations on the condi 
tions for low, moderate, and high stringency are well known 
in the art and may be used with the current invention. 
The terms “nucleic acid” or “nucleic acid molecule” refer 
to a deoxyribonucleotide or ribonucleotide polymer in either 
single- or double-stranded form, and unless otherwise lim 
ited, would encompass known analogs of natural nucleotides 
that can function in a similar manner as naturally occurring 
nucleotides. A “nucleotide sequence” also refers to a poly 
nucleotide molecule or oligonucleotide molecule in the form 
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of a separate fragment or as a component of a larger nucleic 
acid. The nucleotide sequence or molecule may also be 
referred to as a “nucleotide probe.” Some of the nucleic acid 
molecules of the invention are derived from DNA or RNA 
isolated at least once in substantially pure form and in a 
quantity or concentration enabling identi?cation, manipula 
tion, and recovery of its component nucleotide sequence by 
standard biochemical methods. Examples of such methods, 
including methods for PCR protocols that may be used 
herein, are disclosed in Sambrook et al. Molecular Cloning: A 
Laboratory Manual, 2nd ed., Cold Spring Harbor Laboratory 
Press, New York (1989), Ausubel, F. A., et al., eds., Current 
Protocols in Molecular Biology, John Wiley and Sons, lnc., 
NewYork (1987), and Innis, M., et al. (Eds.) PCR Protocols: 
A Guide to Methods and Applications, Academic Press, San 
Diego, Calif. (1990). Reference to a nucleic acid molecule 
also includes its complement as determined by the standard 
Watson-Crick base-pairing rules, with uracil (U) in RNA 
replacing thymine (T) in DNA, unless the complement is 
speci?cally excluded. 
As described herein, the nucleic acid molecules of the 
invention include DNA in both single-stranded and double 
stranded form, as well as the DNA or RNA complement 
thereof. DNA includes, for example, DNA, genomic DNA, 
chemically synthesized DNA, DNA ampli?ed by PCR, and 
combinations thereof. Genomic DNA, including translated, 
non-translated and control regions, may be isolated by con 
ventional techniques, e. g., using any one of the cDNAs of the 
invention, or suitable fragments thereof, as a probe, to iden 
tify a piece of genomic DNA which can then be cloned using 
methods commonly known in the art. 
Polypeptides encoded by the nucleic acids of the invention 
are encompassed by the invention. As used herein, reference 
to a nucleic acid “encoding” a protein or polypeptide encom 
passes not only cDNAs and other intronless nucleic acids, but 
also DNAs, such as genomic DNA, with introns, on the 
assumption that the introns included have appropriate splice 
donor and acceptor sites that will ensure that the introns are 
spliced out of the corresponding transcript when the tran 
script is processed in a eukaryotic cell. Due to the degeneracy 
of the genetic code wherein more than one codon can encode 
the same amino acid, multiple DNA sequences can code for 
the same polypeptide. Such variant DNA sequences can result 
from genetic drift or arti?cial manipulation (e.g., occurring 
during PCR ampli?cation or as the product of deliberate 
mutagenesis of a native sequence). Deliberate mutagenesis of 
a native sequence can be carried out using numerous tech 
niques well known in the art. For example, oligonucleotide 
directed site-speci?c mutagenesis procedures can be 
employed, particularly where it is desired to mutate a gene 
such that predetermined restriction nucleotides or codons are 
altered by substitution, deletion or insertion. Exemplary 
methods of making such alterations are disclosed by Walder 
et al. (Gene 42:133, 1986); Bauer et al. (Gene 37:73, 1985); 
Craik (BioTechniques, Jan. 12-19, 1985); Smith et al. (Ge 
netic Engineering: Principles and Methods, Plenum Press, 
1981); Kunkel (Proc. Natl. Acad. Sci. USA 82:488, 1985); 
Kunkel et al. (Methods in Enzymol. 154.367, 1987). The 
present invention thus encompasses any nucleic acid capable 
of encoding a protein of the current invention. 
The current invention provides for isolated polypeptides. 
As used herein, the term “polypeptides” refers to a genus of 
polypeptide or peptide fragments that encompass the amino 
acid sequences identi?ed herein, as well as smaller frag 
ments. Alternatively, a polypeptide may be de?ned in terms of 
its antigenic relatedness to any peptide encoded by the nucleic 
acid sequences of the invention. Thus, in one embodiment, a 
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polypeptide within the scope of the invention is de?ned as an 
amino acid sequence comprising a linear or 3-dimensional 
epitope shared with any peptide encoded by the nucleic acid 
sequences of the invention. Alternatively, a polypeptide 
within the scope of the invention is recognized by an antibody 
that speci?cally recognizes any peptide encoded by the 
nucleic acid sequences of the invention. Antibodies are 
de?ned to be speci?cally binding if they bind polypeptides of 
the invention with a K, of greater than or equal to about 
107M_l, such as greater than or equal to 108M_l. As used 
herein, the term “isolated,” in reference to polypeptides or 
proteins, means that the polypeptide or protein is substan 
tially removed from polypeptides, proteins, nucleic acids, or 
other macromolecules with which it, or its analogues, occurs 
in nature. Although the term “isolated” is not intended to 
require a speci?c degree of purity, typically, the protein will 
be at least about 75% pure, more typically at least about 90% 
pure, preferably at least about 95% pure, and more preferably 
at least about 99% pure. 
A polypeptide “variant” as referred to herein means a 
polypeptide substantially homologous to a native polypep 
tide, but which has an amino acid sequence different from that 
encoded by any of the nucleic acid sequences of the invention 
because of one or more deletions, insertions or substitutions. 
Variants can comprise conservatively substituted sequences, 
meaning that a given amino acid residue is replaced by a 
residue having similar physiochemical characteristics. See 
Zubay, Biochemistry, Addison-Wesley Pub. Co., (1983). It is 
a well-established principle of protein and peptide chemistry 
that certain amino acids substitutions, entitled “conservative” 
amino acid substitutions, can frequently be made in a protein 
or a peptide without altering either the con?rmation or the 
function of the protein or peptide. Such changes include 
substituting any of isoleucine (I), valine (V), and leucine (L) 
for any other of these amino acids; aspartic acid (D) for 
glutamic acid (E) and vice versa; glutamine (Q) for aspar 
agine (N) and vice versa; and serine (S) for threonine (T) and 
vice versa. 
The above-mentioned substitutions are not the only amino 
acid substitutions that can be considered “conservative.” 
Other substitutions can also be considered conservative, 
depending on the environment of the particular amino acid. 
For example, glycine (G) and alanine (A) can frequently be 
interchangeable, as can be alanine and valine (V). Methionine 
(M), which is relatively hydrophobic, can frequently be inter 
changed with leucine and isoleucine, and sometimes with 
valine. Lysine (K) and arginine (R) are frequently inter 
changeable in locations in which the signi?cant feature of the 
amino acid residue is its charge and the differing pK’ s of these 
two amino acid residues are not signi?cant. Still other 
changes can be considered “conservative” in particular envi 
ronments. 
The effects of such substitutions can be calculated using 
substitution score matrices such PAM120, PAM-200, and 
PAM-250 as discussed in Altschul, (J. Mol. Biol. 219:55565 
(1991)). Other such conservative substitutions, for example, 
substitutions of entire regions having similar hydrophobicity 
characteristics, are well known. 
Naturally-occurring peptide variants are also encompassed 
by the invention. Examples of such variants are proteins that 
result from alternate mRNA splicing events or from pro 
teolytic cleavage of the polypeptides described herein. Varia 
tions attributable to proteolysis include, for example, differ 
ences in the N- or C-termini upon expression in different 
types of host cells, due to proteolytic removal of one or more 
terminal amino acids from the polypeptides encoded by the 
sequences of the invention. 



















